



## Review Article

# Review On : Breast Cancer Their Diagnosis Treatment And Therapies Used

M. B. Gunjal\*, M. G. Shaikh, M. S. Adhikar, S. R. Agrawal

Nandkumar Shinde College of pharmacy vaijapur, Dr Babasaheb Ambedkar Technological University Lonere.

### ARTICLE INFO

Received: 06 Dec 2023

Accepted: 08 Dec 2023

Published: 13 Dec 2023

#### Keywords:

Breast cancer treatment, local therapy, adjuvant therapy, breast-conserving therapy, mastectomy, neoadjuvant chemotherapy, breast cancer surveillance, bosom Treatment.

#### DOI:

10.5281/zenodo.10369595

### ABSTRACT

Bosom malignant growth treatment is multidisciplinary. Most of ladies with beginning phase bosom disease are possibility for bosom saving a medical procedure with radiotherapy or mastectomy. The gamble of neighborhood repeat and the opportunity of endurance doesn't vary with these methodologies. Sentinel hub biopsy is utilized for axillary arranging, and individualized approaches are limiting the requirement for axillary analyzation in sentinel hub positive ladies. Adjuvant fundamental treatment is utilized in most of ladies in light of demonstrated endurance benefit, and sub-atomic profiling to individualize therapy in view of hazard is currently a clinical reality for patients with chemical receptor-positive malignant growths. Follow-up reconnaissance comprises of a set of experiences, actual assessment, and yearly mammography. Following adjuvant fundamental treatment, there is presently no proof that standard imaging further develops results without any side effects.

### INTRODUCTION

The identification and management of invasive breast cancer necessitates interdisciplinary cooperation. Establishing a diagnosis and guiding surgical decisions about the care of the main tumor, staging of the axilla, and the order of therapy all depend heavily on diagnostic imaging work-up and biopsy[i]. The extent of the illness is evaluated upon the confirmation of a breast cancer diagnosis, which, for the most part, decides whether or not preoperative (neoadjuvant)

systemic therapy is necessary .Worldwide, bosom malignant growth is the most well-known disease inladies, other than nonmelanoma skin malignant growth. More than 250 000 new instances of bosom malignant growth were analyzed in the US in 2017, and bosom disease will be analyzed in 12% of all ladies in the US over their lifetimes[ii]

Bosom disease is the most well-known type of malignant growth, representing 25% of all disease analysis around the world; it is the main source of

\*Corresponding Author: M. B. Gunjal

Address: Nandkumar Shinde College of pharmacy vaijapur, Dr Babasaheb Ambedkar Technological University Lonere.

Email ✉: [sanjaygunjal1790@gmail.com](mailto:sanjaygunjal1790@gmail.com)

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.



disease related mortality in ladies Most of ladies with bosom disease are determined to have beginning phase bosom malignant growth instead of territorially progressed or metastatic disease, when sickness is restricted to the bosom with or without provincial lymph hub association. Therapy of bosom disease when it is analyzed at a beginning phase is related with diminished dangers.

Privately progressed bosom malignant growth (LABC) is an exceptionally normal clinical show of mammary carcinoma in non-industrial nations (30% to 60%). Notwithstanding efficient screening, mammography programs and broad public schooling lobbies for early discovery of bosom disease in the USA, the occurrence of LABC is still around 10%-20%. LABC is a heterogeneous gathering of cancers of fluctuating clinical introductions and natural way of behaving whose just normal bonds are the presence of a huge essential cancer, or broad provincial lymph hub association, and the shortfall of any proof of far off metastases. Some patients have a fast neoplastic development, though others present with a long history of cancer development [iv].





Fig-1 world wide cancer Growth

**Classification:**



**1. Instructive Cancer:**

Intrusive bosom disease of no unique sort (NST), previously known as obtrusive ductal carcinoma is the most incessant subgroup (40-80%)[v]]. This type is analyzed of course as a growth that neglects to be characterized into one of the histological exceptional sorts Around 25% of obtrusive bosom tumors present particular development designs and cytological highlights, subsequently, they are perceived as unambiguous subtypes (e.g., obtrusive lobular carcinoma, cylindrical, mucinous A, mucinous B, neuroendocrine)vi].

**2. Luminal Breast Cancer:**

Luminal bosom diseases are emergency room positive growths that contain practically 70% of all instances of bosom tumors in Western populaces [vi]. Most generally Luminal-like malignant growths present as IBC of no extraordinary subtype, yet they may rarely separate into obtrusive lobular, cylindrical, intrusive cribriform, mucinous, and obtrusive micropapillary carcinomas [vI.vii]. Two primary natural cycles: multiplication related pathways and luminal-managed pathways recognize Luminal-like

cancers into Luminal A and B subtypes with various clinical results.

### 3. HER2-Enriched Breast Cancer:

The HER2-enriched subtype makes up 10-15% of breast diseases. It is portrayed by the high articulation of the HER2 with the shortfall of estrogen receptor and PR. This subtype essentially communicates multiplication — related qualities and proteins (e.g., ERBB2/HER2 and GRB7), as opposed to luminal and basal quality and protein subtype. Also, in the HER2-enriched subtype there is proof of mutagenesis interceded by APOBEC3B [viii,ix,x].

### 4. Basal-like/ Triple Negative Breast cancer:

The Triple-Negative Breast Malignant growth (TNBC) is a heterogeneous assortment of breast diseases portrayed as estrogen receptor negative, PR-negative, and HER2-negative. They comprise around 20% of all breast tumors. TNBC is more normal among ladies more youthful than 40 years old and African-American ladies. The greater part (around 80%) of breast tumors emerging in BRCA1 germline change are TNBC, while 11-16% of all TNBC harbor BRCA1 or BRCA2 germline transformations [xi]. TNBC will in general be organically forceful and is frequently connected with a more regrettable visualization. The most widely recognized histology seen in

#### ❖ Sign and Symptoms of breast Cancer:

Signs and symptoms of breast cancer may include:

- A breast lump or thickening that feels different from the surrounding tissue
- Change in the size, shape or appearance of a breast
- Changes to the skin over the breast, such as dimpling

TNBC is penetrating ductal carcinoma, however it might likewise give as medullary-like malignant growths a noticeable lymphocytic invade; metaplastic malignant growths, which might show squamous or axile cell separation; also, uncommon extraordinary sort malignant growths like adenoid cystic carcinoma (AdCC) [xii,xiii,xiv].

### 5. Claudin-Low Breast Cancer:

Claudin-low (CL) breast diseases are unfortunate visualization growths being for the most part estrogen receptor negative, PR-negative, and HER2-negative. CL growths represent 7-14% of generally obtrusive breast diseases. No distinctions in endurance rates were seen between claudin-low cancers and other poor-visualization subtypes (Luminal B, HER2-enriched, and Basal-like). CL subtype is described by the low articulation of qualities associated with cell bond, including claudins 3, 4, and 7, occludin, and E-cadherin [xvi,xvii]. Moreover, these growths show high articulation of epithelial-mesenchymal change (EMT) qualities and undifferentiated cell like quality articulation designs. Additionally, CL growths have stamped safe and stromal cell invasion [18]. Because of their less separated state and a preventive impact of the EMT-related record factor, ZEB1 CL cancers are frequently genomically stable [xix,xx].

- A newly inverted nipple
- Peeling, scaling, crusting or flaking of the pigmented area of skin surrounding the nipple (areola)
- Redness or pitting of the skin over your breast, like the skin of an organ [xxi].




Fig -2 Symptom and sign of breast cancer

• **Risk Factors of Breast Cancer:**

The number of risk factors of breast cancer is significant and includes both modifiable factors and non-modifiable factors.

Non-Modifiable Factors	Modifiable Factors
Female sex	Hormonal replacement therapy
Older age	Diethylstilbestrol
Family history (of breast or ovarian cancer)	Physical activity
Genetic mutations	Overweight/obesity
Race/ethnicity	Alcohol intake
Pregnancy and breastfeeding	Smoking
Menstrual period and menopause	Insufficient vitamin supplementation
Density of breast tissue	Excessive exposure to artificial light
Previous history of breast cancer	Intake of processed food
Non-cancerous breast diseases.	Exposure to chemicals
Previous radiation therapy	Other drugs

• **Prevention for breast cancer:**

**Breastfeeding and breast cancer prevention**

A recent study, Breastfeeding and the Prevention of Breast Cancer: a Retrospective Review of Clinical Histories research reveals the fact that parous woman who is breastfeeding for over six months protects herself from breast cancer when she is a non-smoker. A retrospective study was conducted in Granada San Cecilio University Hospital in Spain and proved by the histories of each patient. Generally, records of 504 female patients from 19 to 91 years of age were analyzed. Besides, some other risk factors such as obesity, alcohol consumption, smoking, and family history of cancer were taken into account[xii]. Kotsopoulos et al. (2012) argue that among carriers of BRCA1 gene breastfeeding for at least one year reduces the risk of breast cancer “by 32 percent, and breastfeeding for two or more years reduces breast cancer development risk by about 19 percent each year”. In its turn, speaking about BRCA2 gene carriers, the risk of breast cancer was not statistically significant. It is a known fact that pregnancy and breastfeeding protect women from

developing breast cancer. Both processes stimulate the formation of breast epithelium and suppress estrogen levels, which is conducive to the emergence of this form of cancer (Kotsopoulos et al., 2012)[xviii]. In this situation, researchers rely on the maternity ward nurses. They should tell mothers about the benefits of breastfeeding that are not only strengthening the immune system of the baby, but also protecting his mother from the dangerous disease (González-Jiménez, García, Aguilar, Padilla, & Álvarez, 2013)[xxiv].

- **Diagnosis for breast cancer:**

- **General examination**

- 1. Breast exam.**

Your doctor will check both of your breasts and lymph nodes in your armpit, feeling for any lumps or other abnormalities.

- 2. Mammogram.**

A mammogram is an X-ray of the breast. Mammograms are commonly used to screen for breast cancer. If an abnormality is detected on a screening mammogram, your doctor may recommend a diagnostic mammogram to further evaluate that abnormality [xxv].

- 3. Breast ultrasound.**

Ultrasound uses sound waves to produce images of structures deep within the body. Ultrasound may be used to determine whether a new breast lump is a solid mass or a fluid-filled cyst [xxvi].

- 4. Removing a sample of breast cells for testing (biopsy).**

A biopsy is the only definitive way to make a diagnosis of breast cancer. During a biopsy, your doctor uses a specialized needle device guided by X-ray or another imaging test to extract a core of tissue from the suspicious area. Often, a small metal marker is left at the site within your breast so the area can be easily identified on future imaging tests. Biopsy samples are sent to a laboratory for analysis where experts determine whether the cells are cancerous. A biopsy sample is also analyzed to determine the type of cells

involved in the breast cancer, the aggressiveness (grade) of the cancer, and whether the cancer cells have hormone receptors or other receptors that may influence your treatment options [xxvii].

- 5. Breast magnetic resonance imaging (MRI).**

An MRI machine uses a magnet and radio waves to create pictures of the interior of your breast. Before a breast MRI, you receive an injection of dye. Unlike other types of imaging tests, an MRI doesn't use radiation to create the images [xxviii].

- **Treatment for breast cancer :**

Your primary care physician decides your breast malignant growth therapy choices in light of your sort of breast disease, its stage and grade, size, and whether the malignant growth cells are delicate to chemicals. Your primary care physician likewise thinks about your general wellbeing and your own inclinations. Most ladies go through a medical procedure for breast disease and many likewise get extra therapy after medical procedure, like chemotherapy, chemical treatment or radiation. Chemotherapy could likewise be utilized before a medical procedure in specific circumstances. There are numerous choices for breast malignant growth treatment, and you might feel overpowered as you settle on complex conclusions about your treatment. Consider looking for a second assessment from a breast expert in a breast community or facility. Converse with different ladies who have confronted a similar choice [xxix].

- 1. Eliminating the breast malignant growth (lumpectomy).**

During a lumpectomy, which might be alluded to as breast preserving a medical procedure or wide excision, the specialist eliminates the growth and a little edge of encompassing breast tissue [xxx]. A lumpectomy might be suggested for eliminating more modest growths. Certain individuals with bigger cancers might go through chemotherapy before medical procedure to recoil





a growth and make it conceivable to eliminate totally with a lumpectomy method [xxxix].

## **2. Eliminating the whole bosom (mastectomy).**

A mastectomy is an activity to eliminate all of your bosom tissue. Most mastectomy strategies eliminate all of the bosom tissue — the lobules, conduits, greasy tissue and some skin, including the areola and areola (aggregate or straightforward mastectomy). Fresher careful procedures might be a choice in chose cases to work on the presence of the bosom. Skin-saving mastectomy and areola saving mastectomy are progressively normal tasks for bosom disease[xxxix].

## **3. Eliminating a set number of lymph hubs (sentinel hub biopsy).**

To decide if malignant growth has spread to your lymph hubs, your specialist will talk about with you the job of eliminating the lymph hubs that are quick to get the lymph seepage from your cancer. Assuming no malignant growth is tracked down in those lymph hubs, the possibility finding disease in any of the leftover lymph hubs is little and no different hubs should be taken out[xxxix].

## **4. Eliminating a few lymph hubs (axillary lymph hub analyzation).**

Assuming disease is found in the sentinel lymph hubs, your specialist will talk about with you the job of eliminating extra lymph hubs in your armpit[xxxix].

## **5. Eliminating the two bosoms.**

A few ladies with malignant growth in one bosom might decide to have their other (sound) bosom eliminated (contralateral prophylactic mastectomy) on the off chance that they have an extremely expanded hazard of disease in the other bosom as a result of a hereditary inclination or solid family ancestry. Most ladies with bosom disease in one bosom won't ever foster malignant growth in the other bosom. Talk about your bosom malignant growth risk with your primary care physician, alongside the advantages and dangers of this technique [xxxix].

## **• Therapy used in breast cancer :**

### **1. Radiation therapy:**

Radiation treatment utilizes powerful light emissions, like X-beams and protons, to kill disease cells. Radiation treatment is commonly done utilizing an enormous machine that goes for the gold at your body (outer bar radiation). However, radiation should likewise be possible by setting radioactive material inside your body (brachytherapyxxxix) Outside pillar radiation of the entire bosom is generally utilized after a lumpectomy. Bosom brachytherapy might be a choice after a lumpectomy in the event that you have an okay of disease repeat. Specialists may likewise prescribe radiation treatment to the chest wall after a mastectomy for bigger bosom malignant growths or tumors that have spread to the lymph hubs. Bosom malignant growth radiation can endure from three days to about a month and a half, contingent upon the therapy. A specialist who utilizes radiation to treat disease (radiation oncologist) figures out which therapy is best for you in light of your circumstance, your malignant growth type and the area of your cancer. Symptoms of radiation treatment incorporate weakness and a red, burn from the sun like rash where the radiation is pointed. Bosom tissue may likewise seem enlarged or all the more firm. Seldom, more-difficult issues might happen, like harm to the heart or lungs or, once in a blue moon, second malignant growths in the treated region[xxxix].

### **2. Chemotherapy:**

Chemotherapy utilizes medications to obliterate quickly developing cells, like disease cells. Assuming your disease has a high gamble of returning or spreading to one more piece of your body, your primary care physician might prescribe chemotherapy after medical procedure to diminish the opportunity that the malignant growth will repeat .Chemotherapy is once in a while given before a medical procedure in ladies with bigger



bosom growths. The objective is to shrivel a cancer to a size that makes it more straightforward to eliminate with a medical procedure. Chemotherapy is additionally utilized in ladies whose disease has proactively spread to different pieces of the body. Chemotherapy might be prescribed to attempt to control the malignant growth and lessening any side effects the disease is causing. Chemotherapy secondary effects rely upon the medications you get. Normal incidental effects incorporate balding, queasiness, spewing, weakness and an expanded gamble of fostering a contamination. Intriguing incidental effects can incorporate untimely menopause, barrenness (if premenopausal), harm to the heart and kidneys, nerve harm, and, once in a while, blood [xxxviii].

- **Chemical treatment:**

Chemical treatment — maybe more appropriately named chemical hindering treatment — is utilized to treat bosom tumors that are delicate to chemicals. Specialists allude to these malignant growths as estrogen receptor positive (emergency room positive) and progesterone receptor positive (PR positive) diseases. Chemical treatment can be utilized previously or after medical procedure or different therapies to diminish the opportunity of your malignant growth returning. In the event that the disease has previously spread, chemical treatment might psychologist and control it [xxxix].

- **1. Hormone therapy:**

Medicines that can be utilized in chemical treatment include: Meds that block chemicals from appending to malignant growth cells (specific estrogen receptor modulators) Meds that prevent the body from making estrogen after menopause (aromatase inhibitors) Medical procedure or drugs to stop chemical creation in the ovaries Chemical treatment incidental effects rely upon your particular treatment, yet may incorporate hot blazes, night sweats and vaginal dryness. More

serious incidental effects incorporate a gamble of bone diminishing and blood clumps [XL].

- **2. Immunotherapy:**

Immunotherapy utilizes your invulnerable framework to battle disease. Your body's sickness battling invulnerable framework may not go after your malignant growth on the grounds that the disease cells produce proteins that blind the insusceptible framework cells. Immunotherapy works by impeding that interaction. Immunotherapy may be a choice assuming you have triple-negative bosom malignant growth, and that implies that the disease cells don't have receptors for estrogen, progesterone or HER2 [XLI].

- **CONCLUSION:**

This review obviously shows that the treatment of BC is perplexing and is continually developing with an enormous number of continuous clinical preliminaries on arising treatments. Without a doubt, the BC sub-atomic subtype will decide the customized remedial methodology, for example, designated medicines like endocrine treatment for HR+ BC or hostile to HER2 treatment for HER2+ BC. These treatments have exhibited their security and adequacy in treating BC throughout the long term. In any case, it is vital for go past these regular medicines as BC is a complicated illness and not all patients can profit from customized treatment. One of the significant difficulties in BC treatment is tracking down compelling treatments to treat TNBC patients since ordinary designated treatments can't be controlled for this particular BC subtype, which has the most horrendously awful endurance results.

- **ACKNOWLEDGEMENT:**

In this review all authors are equally contributed all authors are declared that there is no conflict of interest regarding the publication of this paper and no any funding authority

- **REFERENCES**

1. [Www.wikipedia.com](http://www.wikipedia.com)



2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2018;68(6):394-424. doi:10.3322/caac.21492
3. National Institutes of Health; National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer stat facts: female breast cancer. <https://seer.cancer.gov/statfacts/html/breast.html>. Accessed January 23, 2018.
4. Caughran J, Braun TM, Breslin TM, et al. The effect of the 2009 USPSTF breast cancer screening recommendations on breast cancer in Michigan: a longitudinal study. *Breast J.* 2018;24(5):730-737. doi:10.1111/tbj.13034
5. Morrow M. Physical examination of the breast. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. *Diseases of the Breast*. Philadelphia, PA: Wolters Kluwer Health; 2014:chap3. [3:02 pm, 09/11/2023] m: Weigelt, B.; Horlings, H.M.; Kreike, B.; Hayes, M.M.; Hauptmann, M.; Wessels, L.F.A.; De Jong, D.; van de Vijver, M.; Veer, L.J.V.;
6. Peterse, J.L. Refinement of breast cancer classification by molecular characterization of histological special types. *J. Pathol.* 2008, 216, 141–150.
7. Erber, R.; Hartmann, A. Histology of Luminal Breast Cancer. *Breast Care* 2020, 15, 327–336
8. Howlader, N.; Altekruse, S.F.; Li, C.I.; Chen, V.W.; Clarke, C.A.; Ries, L.A.G.; Cronin, K.A. US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status. *J. Natl. Cancer Inst.* 2014, 106, djuOncolVIi
9. Weigelt, B.; Geyer, F.C.; Reis-Filho, J.S. Histological types of breast cancer: How special are they? *Mol. Oncol.* 2010, 4, 192–208.
10. Makki, J. Diversity of Breast Carcinoma: Histological Subtypes and Clinical Relevance. *Clin. Med. Insights Pathol.* 2015, 8, 23–31.[CrossRef]
11. Raj-Kumar, P.-K.; Liu, J.; Hooke, J.A.; Kovatich, A.J.; Kvecher, L.; Shriver, C.D.; Hu, H. PCA-PAM50 improves consistency between breast cancer intrinsic and clinical subtyping reclassifying a subset of luminal A tumors as luminal B. *Sci. Rep.* 2019, 9, 7956.
12. Ranjit, K. Breast cancer. *Lancet* 2005, 365, 1742.
13. Roberts, S.A.; Lawrence, M.S.; Klimczak, L.J.; Grimm, S.A.; Fargo, D.; Stojanov, P.; Kiezun, A.; Kryukov, G.; Carter, S.L.; Saksena, G.; et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. *Nat. Genet.* 2013, 45, 970–976.
14. Plasilova, M.L.; Hayse, B.; Killelea, B.K.; Horowitz, N.R.; Chagpar, A.B.; Lannin, D.R. Features of triple-negative breast cancer.
15. Newman, L.A.; Reis-Filho, J.S.; Morrow, M.; Carey, L.A.; King, T.A. The 2014 Society of Surgical Oncology Susan G. Komen for
16. the Cure Symposium: Triple-Negative Breast Cancer. *Ann. Surg. Oncol.* 2014, 22, 874–882. 2016, 95, subtyping. Pareja, F. Triple-negative breast cancer: The importance of molecular and histologic subtyping, and recognition of low-grade variants. *NPJ Breast Cancer* 2016, 2, 16036.
17. Wetterskog, D. Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast
18. Badve, S.; Dabbs, D.J.; Schnitt, S.J.; Baehner, F.L.; Decker, T.; Eusebi, V.; Fox, S.; Ichihara, S.; Jacquemier, J.;



20. Lakhani, S.R.; et al. Basal-like and triple-negative breast cancers: A critical review with an emphasis on the implications for pathologists and oncologists. *Mod. Pathol.* 2010, 24, 157–167.. *J. Pathol.* 2012, 226, 84–96
21. Prat, A.; Parker, J.S.; Karginova, O.; Fan, C.; Livasy, C.; Herschkowitz, J.I.; He, X.; Perou, C.M. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. *Breast Cancer Res.* 2010, 12, R68.
22. Hennessy, B.T.; Gonzalez-Angulo, A.-M.; Stemke-Hale, K.; Gilcrease, M.Z.; Krishnamurthy, S.; Lee, J.-S.; Fridlyand, J.; Sahin, A.A.;
23. Agarwal, R.; Joy, C.; et al. Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-MesenchymRes2
24. Transition and Stem Cell Characteristics. *Cancer Res.* 2009, 69, 4116–41Whel.Dias, K.; Dvorkin-Gheva, A.; Hallett, R.M.; Wu, Y.; Hassell, J.; Pond, G.R.; Levine, M.; Whelan, T.; Bane, A.L. Claudin-Low Breast Cancer; Clinical & Pathological Characteristics. *PLoS ONE* 2017, 12, e0168669.
25. Morel, A.-P.; Ginestier, C.; Pommier, R.M.; Cabaud, O.; Ruiz, E.; Wicinski, J.; Devouassoux-Shisheboran, M.; Combaret, V.; Finetti, P.; Chassot, C.; et al. A stemness-related ZEB1–MSRB3 axis governs cellular pliancy and breast cancer genome stability. *Nat. Med.* 2017, 23, 568–578
26. Acton, A. (2013). *Breast Cancer New Insights for the Healthcare Professional.* Atlanta, Georgia: Scholarly Editions.
27. .González-Jiménez, E., García, P., Aguilar, M., Padilla, C., & Álvarez, J. (2013). Breastfeeding and the Prevention of Breast Cancer: a Retrospective Review of Clinical Histories. *Journal of Clinical Nursing*, 23(1), 2397-2403.
28. 3.Kotsopoulos, J., Lubinski, J., Salmena, L., Lynch, H., Kim-Sing, C., Foulkes, W., Ghadirian, P., Neuhausen, S., Demsky, R., Tung, N., Ainsworth, P., Senter, L., Eisen, A., Eng, C., Singer, C., Ginsburg, O., Blum, J., Huzarski, T., Poll, A., Sun, P. and Narod, S. (2012). Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research*, 14(2), p.R42
29. .Hennessy, B.T.; Gonzalez-Angulo, A.-M.; Stemke-Hale, K.; Gilcrease, M.Z.; Krishnamurthy, S.; Lee, J.-S.; Fridlyand, J.; Sahin, A.A.; Agarwal, R.; Joy, C.; et al. Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics. *Cancer Res.* 2009, 69, 4116–4124.
30. Youtube.com ganeshay medical educaganasha72
31. Hennessy, B.T.; Gonzalez-Angulo, A.-M.; Stemke-Hale, K.; Gilcrease, M.Z.; Krishnamurthy, S.; Lee, J.-S.; Fridlyand, J.; Sahin, A.A.; Agarwal, R.; Joy, C.; et al. Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics. *Cancer Res.* 2009, 69, 4116–4124.
32. Folkerd, E.; Dowsett, M. Sex hormones and breast cancer risk and prognosis. *Breast* 2013, 22, S38–S43.
33. Stat Bite: Lifetime Probability among Females of Dying of Cancer. *JNCI J. Natl. Cancer Inst.* 2004, 96, 1311–1321.9
34. Seal, S.; The Breast Cancer Susceptibility Collaboration (UK); Thompson, D.; Renwick, A.; Elliott, A.; Kelly, P.; Barfoot, R.; Chagtai, T.; Jayatilake, H.; Ahmed, M.; et

- al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. *Nat. Genet.* 2006, 38, 1239–1242
35. [www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection/mammograms.html](http://www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection/mammograms.html)
36. [www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection/breast-ultrasound.html](http://www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection/breast-ultrasound.html)
37. [www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection/breast-biopsy.html](http://www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection/breast-biopsy.html)
38. [www.cancer.org/cancer/diagnosis-staging/tests/imaging-tests/mri-for-cancer.html](http://www.cancer.org/cancer/diagnosis-staging/tests/imaging-tests/mri-for-cancer.html)
39. Lumachi, F.; Luisetto, G.; Basso, S.M.M.; Basso, U.; Brunello, A.; Camozzi, V. Endocrine Therapy of Breast Cancer. *Curr. Med. Chem.* 2011, 18, 513–522. [CrossRef]
40. Jones, K.L.; Buzdar, A.U. A review of adjuvant hormonal therapy in breast cancer. *Endocr.-Related Cancer* 2004, 11, 391–406 [CrossRef]
41. Rouzier, R.; Perou, C.; Symmans, W.F.; Ibrahim, N.; Cristofanilli, M.; Anderson, K.; Hess, K.R.; Stec, J.; Ayers, M.; Wagner, P.; et al. Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy. *Clin. Cancer Res.* 2005, 11, 5678–5685.[CrossRef]
42. Lumachi, F.; Luisetto, G.; Basso, S.M.M.; Basso, U.; Brunello, A.; Camozzi, V. Endocrine Therapy of Breast Cancer. *Curr. Med. Chem.* 2011, 18, 513–522. [CrossRef]
43. National Institutes of Health; National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer stat facts: female breast cancer. <https://seer.cancer.gov/statfacts/html/breast.html>. Accessed January 23, 2018.4XL
44. Caughran J, Braun TM, Breslin TM, et al. The effect of the 2009 USPSTF breast cancer screening recommendations on breast cancer in Michigan: a longitudinal study. *Breast J.* 2018;24(5):730-737. doi:10.1111/tbj.13034
45. Caughran J, Braun TM, Breslin TM, et al. The effect of the 2009 USPSTF breast cancer screening recommendations on breast cancer in Michigan: a longitudinal study. *Breast J.* 2018;24(5):730-737. doi:10.1111/tbj.13034

**HOW TO CITE:** M. B. Gunjal\*, M. G. Shaikh, M.S. Adhikar, S. R. Agrawal, Review on : Breast cancer their Diagnosis Treatment and Therapies used, *Int. J. in Pharm. Sci.*, 2023, Vol 1, Issue 12, 307- 316. <https://doi.org/10.5281/zenodo.10369595>